It has been reported that NK cells contribute to PD-1/PD-L1 antibody-mediated immunotherapy by expressing PD-L1 as a cytolytic effector (24, 25), while M2 macrophages help to generate an immune-evasive microenvironment in evolved cancers (26, 27). This evidence concerns the gene PDCD1 and cancer.